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Abstract
Background: Business cases are used to provide a structured justification in favour of investing in new projects,
services or interventions. Despite the use of business cases in determining how limited resources will be allocated
within England’s National Health Service (NHS), guidance concerning how to develop and evaluate business cases
in the context of healthcare is inconstant and of varying relevance. This study aimed to develop a new framework
of quality indicators for healthcare-related business cases by analysing the content of expert guidance documents
and a sample of NHS business cases.
Methods: Qualitative document analysis was conducted on guidance documents (n = 7) and existing NHS business
case documents (n = 18). Documents were purposefully sampled using criteria to ensure the framework reflected a
diverse spread of expert opinion, and a varied sample of example business cases from current practice. Data were
analysed using thematic and content analysis, and are presented in a visualised framework.
Results: Seven themes were identified within the qualitative document analysis (purpose, strategic priorities,
options, benefits, costs, risks and evaluation). These themes were described and presented with a framework of
quality indicators for healthcare-related business cases.
Conclusion: To ou`r knowledge, this is the first framework of business case quality indicators designed specifically
for use in a healthcare context. The framework presented in this study has implications for how business cases are
developed and evaluated by decision makers. In the future it would be beneficial to investigate how the framework
could be used in practice as a tool for critical appraisal.
Keywords: Business case, Health providers, Quality, Qualitative, Document analysis, National Health Service, UK
Background
Faced with the challenge of increasing healthcare de-
mands on increasingly limited resources, the develop-
ment and evaluation of business cases provides an
opportunity to examine and decide between alternative
funding options. Decision makers in many health sys-
tems are required to make decisions about how con-
strained resources will be used optimally [1], yet
decisions related to new programmes will vary in the ex-
tent to which they are driven by evidence [2–4]. Busi-
ness cases are routinely used by NHS organisations
when considering whether to invest in new services or
programmes. The quality of these decisions could be in-
fluenced by the quality of the insight that informs them,
and numerous procedures, including the use of business
cases, contribute to this process. Despite this potential
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to impact changes in policy, there is an absence of de-
scriptive, collated and informative guidance on the de-
velopment of healthcare-related business cases.
Business cases are constructed to: outline the rationale
and justification for a change [5], secure support and re-
sources from leadership [6], and provide understanding
about how a change in practice will yield an economic
return on investment [7, 8]. Although business cases
continue to be used to support decision making in
healthcare settings internationally, questions have been
raised regarding the methodological rigor and transpar-
ency of these procedures [9]. A ‘good’ business case will
provide the detail and clarity necessary for decision
makers to make evidence-based decisions, while a ‘poor’
business case may lack persuasion or, in more serious
cases, misinform decision-makers about the relative
strengths and weaknesses of available options. Subse-
quently, there is a need to think critically about the use
of business cases, what should be included in their ‘con-
tent’, and how their quality should be determined.
For clinicians and service providers, business cases
provide a potential evidence-based method for instigat-
ing changes in practice. Published examples in the litera-
ture are diverse and include proposals for embedding
the patient perspective within the delivery of healthcare
[10], raising standards in infectious disease control [11],
part-time employment contracts for nurses [12], art-
therapies to manage symptoms of mental health condi-
tions [13], and new technologies for surgical procedures
[14]. This diversity in examples illustrates how business
cases can be flexibly applied across numerous clinical
contexts.
In England, financial strains within the NHS mean that
decision makers are required to make funding decisions
against a backdrop of increasing pressure to reduce costs
and promote efficiency [15]. In the NHS, these concerns
are arguably most critical within the Clinical Commis-
sioning Groups (CCGs) responsible for planning and
purchasing health services for local populations across
England. Decisions concerning these provisions may be
influenced by business cases, therefore there is a need
for adequate guidance to support their appropriate
utilisation.
Generic advice on how to compile business cases
exists [12]. It is unclear, however, how well used or use-
ful this guidance has been in healthcare settings. Online
resources have been compiled with healthcare in mind
[16], and in some cases guidance for writing business
cases in relation to specific clinical areas has been pub-
lished [17]. There is currently no consensus concerning
which guidance should be followed; further, most of the
available resources do not appear to have undergone any
formal process of peer review. Where health-focused
resources are available, they have frequently been
compiled with specialist clinical areas in mind (such as
Parkinson’s or Heart Disease) and may not be more
broadly applicable. Given these challenges and the po-
tential for business cases to influence healthcare policy
and practice, there is a need to explore the content of
available resources, and to analyse the extent to which
there are consistent quality indicators that emerge across
guidelines, to provide stronger guidance to those putting
together such cases.
This study uses qualitative document analysis to
develop a framework of ‘quality indicators’, drawing on
insights from both available expert guidance documents
and a diverse set of existing business cases developed in
the NHS.
Methods
Design
This study took a qualitative document analysis
approach [18], in response to the nature of the data
(guideline documents and existing business cases) and
the availability of rich, appropriate and previously uncol-
lated written resources. The study team included both
academic and professional expertise in applied health-
care research, economics, health services management,
qualitative methods, and public health. Where applic-
able, we adhered to the Standards for Reporting Qualita-
tive Research (SRQR) guidelines to report the findings of
this study [19].
Data collection
We collected guidance documents (GDs), and business
case documents (BCs) across CCGs in one geographical
region. GDs refer to existing articles and online re-
sources that provide expert advice and support for those
either compiling business cases or appraising the quality
of existing business cases in the public sector. We
collected these documents to capture the ‘best practice’
recommendations made by subject matter experts on
the topic. For comparative purposes, we also collected
BCs to develop a better understanding of the character-
istics of documents used in practice. We supplemented
these BCs with documents associated with meetings
where BC decision-making was undertaken. Documents
were collected on an on-going basis between September
2016 and May 2018. A set of terms were used when
searching online for guidance documents (business case,
guide, guidance, guideline, checklist, advice, instructions,
healthcare and health). This list was informed by terms
contained within a research collaboration agreement
document developed by a team including expertise in
public health, academic research, commissioning, and
primary care.
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Document sampling
A set of complementary sampling strategies were
employed in response to the evolving nature of the project
and structural developments underway in NHS CCGs.
Documents were purposefully sampled, with the aim of
undertaking a rich and in-depth interpretation, rather
than as a systematic attempt to sample documents repre-
sentative of all guidelines and all business cases.
Guidance documents were selected using criterion
sampling. The criteria sought were: (1) documents that
were either peer-reviewed publications or online re-
sources, and (2) documents that explicitly listed instruct-
ive points for those either developing or appraising
business cases. This work was undertaken during a
period of ongoing organisational changes, including the
introduction of NHS Sustainability and Transformation
Partnerships (STPs) across England, therefore it was im-
portant to maintain ongoing dialog with identified ‘gate-
keepers’ within the CCG to gain access to business
cases. Once access to business cases was achieved, indi-
vidual documents were sampled based on heterogeneity
in three characteristics: the year the business case was
produced, clinical programme area, and funding success.
Document collection
In total 25 documents were collected (presented in
Fig. 1). The guidance documents included two peer-
reviewed publications [17, 20] and five online resources
[16, 21–24]. These online resources were either static
webpages or downloadable Microsoft Word/PDF docu-
ments. In addition, 15 NHS business cases were sampled
from three separate financial reporting periods (2014–
15 = 5, 2015–16 = 5 and 2016–17 = 5). All relevant sets
of formal minutes detailing decision-making processes
and the final funding decisions made at CCG board
meetings regarding business cases seeking investment
were also examined, to provide further contextual data
and enrich our understanding of the topic. Ten of the
fifteen business cases were subsequently successfully
funded and were on average 14 pages long (range: 3–29
pages). The business cases were diverse in terms of clin-
ical areas (Mental health, Community services, Promot-
ing independence, Long-term conditions, Urgent/
emergency care, Planned care, Medicines management,
and Dementia), and the type of development they
proposed (Investments, Quality improvement, ‘Spend to
save’, and Prevention).
Data analysis
The document analysis approach was undertaken in line
with methodological guidance, and combines elements
of content analysis and thematic analysis [18]. Content
analysis in the context of document analysis refers to the
process of identifying and collating meaningful sections
of the document text, such as the guidance checklists
contained within published papers. Thematic analysis
was used to examine how patterns within and between
the documents emerge as key themes representative of
Fig. 1 Documents collected for qualitative document analysis
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what ‘good quality’ means within the context of health-
care business cases. Document analyses combine both
analytical approaches, to capitalise on the rich breadth
of content contained within documents [18], whilst also
using a structured approach to handling and organising
the data around key topics [25].
The documents were read concurrently as data collec-
tion progressed, to develop familiarity with the data. The
checklists and recommendations within guidance docu-
ments were entered into a Microsoft Excel spreadsheet to
enable a structured examination of the data. Business
cases were examined in their original format (Microsoft
Word or PDF). Throughout the analysis, a log containing
notes and emergent ideas was frequently updated. Codes
were highlighted throughout the documents to indicate
pertinent points. The codes were examined further, and
emergent patterns were labelled as potential ‘themes’ for
further discussion with the wider study team. Data satur-
ation was achieved when the addition of new documents
to the analysis ceased to contribute to the emergence of
new themes [26]. The themes and the patterns that sup-
ported their emergence were inspected by the wider study
team, and any disagreements were resolved through
discussions. The findings were reported descriptively and
summarised within a visualised framework.
Results
Seven themes were identified: Purpose, Strategic prior-
ities, Options, Risks, Costs, Benefits and Evaluation.
These themes are described below, and graphically rep-
resented in Fig. 2.
Purpose
The need for business cases to contain a clearly articu-
lated goal was frequently referred to across most of the
guidance documents (5/7). Some guidelines suggested
that business cases simply needed to include defined
aims and objectives, while others claimed a more struc-
tured approach should be taken and any included objec-
tives should be: specific, measurable, achievable, realistic
and timely (SMART).
Ensure your objectives are Specific, Measurable,
Achievable, Realistic and Timely (SMART)… Provide a
vision of the end position i.e. the future you seek to
achieve. (GD5).
Despite this, fewer than half of the NHS business cases
we analysed (7/15) included explicitly labelled aims or
objectives. The remaining business cases described the
purpose of the business case in more generic terms as in
the following example.
This business case is to support the implementation of
a CCG commissioned Tier 3 Adult Weight Management
Service. (BC, 2015).
Although most business cases stated which ‘specific’
demographic would be targeted (13/15), this information
was explicitly provided within the objective by only a
small number of the NHS business cases.
Fig. 2 Framework of quality indicators for healthcare business cases
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The primary aim of the service will be to reduce the
incidence of falls in people aged over 65 years and associ-
ated healthcare costs. (BC, 2016).
The objectives identified in the analysed business cases
also typically lacked ‘measurability’ and instead included
unquantified targets as in the following example.
Sufficient commissioned diagnostic assessment capacity
for people referred by General Practitioners. (BC, 2014).
Strategic priorities
Nearly all the guidance documents stressed that business
cases should be positioned within the context of local
and/or national strategic objectives (6/7).
Set the business case within the framework of national
and local priorities (the strategic context) (GD3).
The NHS business cases we reviewed did reflect
strategic priorities; however, they were more likely to
reflect national rather than local concerns, which were
far less clearly articulated.
NICE Guidelines recommend that older people who
present for medical attention because of a fall, or report
recurrent falls, or demonstrate abnormalities of gait and/
or balance should be offered a multifactorial falls risk as-
sessment. (BC, 2016).
It was clear that many of the business cases were im-
plicitly addressing local needs, such as reducing waiting
times. However, only one business case explicitly linked
its proposal to a set of local needs.
Both the [anonymised] Joint Strategic Needs Assess-
ment (2013) and the [anonymised] Health and Wellbeing
Strategy (2013) stress the need for diabetes patients to
have a universal standard of good care. (BC, 2015).
Options
Many of the guidance documents stated that it was im-
portant for business cases to clearly outline a range of
options for decision makers to consider (4/7).
Confirm other options considered to achieve the
scheme’s objectives. (GD7).
Additionally, some guidelines stated that that one of
the discussed options should be a ‘do nothing’ scenario,
which deals with the consequences of not implementing
any changes.
Are results of each option presented clearly including
do nothing/minimum option? (GD1).
In contrast to the expectations outlined within guide-
lines, it was notable that the NHS business cases we
reviewed rarely outlined alternative options. However,
some of the business cases (3/15) presented partial or
full option-appraisals, and explored the benefits and dis-
advantages of each option, including one scenario where
the implications of doing nothing were explored.
Option 1/Do nothing - CCG(s) to agree how future de-
mand will be managed which cannot be met by the
service. Option 2 - Recruit additional staff on a fixed
term basis to assist with the waiting list. Option 3 - Re-
cruit additional staff on a permanent basis. Option 4 -
Provide a safe service to bariatric patients (BC, 2016).
Risks
The importance of understanding risks associated with
the proposed investment reoccurred throughout the
guidance documents (4/7). Beyond simply identifying
risky outcomes, a comprehensive business case is ex-
pected to outline how these risks will be managed and
what process will be put in place to mitigate their impact
on the success of the proposed programme.
The risks have been clearly outlined and a risk mitiga-
tion strategy is in place. (GD5).
All the NHS business cases (15/15) outlined a set of
possible risks associated with undertaking the proposed
change in service delivery. In most cases (12/15) plans
were also outlined to describe how these risks would be
mitigated.
The risk of implementing [programme name] will be
mitigated through introducing the new service as a ‘test
and learn’ pilot based initially in one GP cluster area.
(BC, 2016).
‘Monitoring’ implementation was the most frequently
stated method of mitigating risk.
Capacity – there has not been a service like this before
in [anonymised region] so it is difficult to predict
demand. Mitigation =Monitor referrals to ensure appro-
priateness & regularly review workload and project out-
comes. (BC, 2015).
In some business cases however, there was a greater
emphasis on the need to provide more explicit points
surrounding how these risks would be tackled, above
and beyond monitoring adverse outcomes.
The risks of implementing a Tier 3 service will be
mitigated through introducing the new service as a Test
and Learn pilot. This will allow the CCG to test and
evaluate the new Tier 3 model (the demand, costs, out-
comes) before a full procurement exercise takes place for
a more permanent solution. (BC, 2015).
Costs
Almost all the reviewed guidelines documented several
ways in which the costs associated with business cases
should be evidenced and presented (6/7). Understanding
what is already funded, quantifying and itemising costs,
and clarifying where funds would come from were
flagged as important considerations.
Consider finances - Be clear on what services your
organisation currently pays for, how much any improve-
ments will cost and where the funding will come from.
(GD2).
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Within one guideline, costs and potential benefits were
considered simultaneously.
Are all economic costs and benefits clearly calculated
for each year covered by the proposal with Net Present
Value (NPV) calculated correctly? (GD1).
All of the analysed business cases (15/15) presented
numerical figures for how much investment their initia-
tives required. Some of these business cases outlined the
cost attached to employing a new member of staff, while
more detailed cases outlined a more in-depth breakdown
of costs as in the following example.
Training in exercise for back care (£600), Co-ordinator/
provider 0.5 WTE for 9 months (£11,820), Venue costs
(£3640), Co-ordinator travel costs (£250), and Contin-
gency (e.g. sickness cover) (£500), and Total (£16,810).
(BC, 2016).
Benefits
All the guidance documents described alternative ways
of detailing expected benefits, in terms of the positive
outcomes resulting from investment. Within these docu-
ments, benefits were predominantly discussed in terms
of cost-savings or quality improvements.
Confirm the scheme benefits – including financial
(cash releasing and non cash releasing) and non finan-
cial (quantifiable and non quantifiable) and how the
scheme delivers value for money. (GD7).
One guideline document also highlighted the need to
be realistic about the estimated benefits, in light of
known and unknown threats.
Is optimism bias properly included and aligned with
risk? (GD1).
Within existing business cases, benefits were consist-
ently predicted in terms of financial consequences.
Savings from such investments elsewhere on the same
scale as proposed for [anonymised region] have delivered
savings between £83,580 and £585,000. (BC, 2016).
In other cases, benefits were also descriptively
expressed in terms of improvements to the service pro-
vided specifically to patients.
Maximise a patient’s physical and psychological health
through lifestyle advice and education on medication,
exercise and breathlessness. (BC, 2015).
Evaluation
A small number of the guidance documents highlighted
that it was necessary for business cases to include plans
for identifying positive and negative outcomes if the
planned initiative was successfully funded (2/7).
Does the plan include post implementation evaluation
arrangements (including who, when, how, and costs)?
(GD1).
Although evaluation was highlighted in a minority of
guidance documents, most of the business cases
proposed ways in which their service could be moni-
tored and subsequently evaluated (11/15). These evalu-
ation plans differed in terms of: what was monitored,
who would be involved in the evaluation, what type of
analysis would be undertaken and the time periods that
the evaluation would be conducted within.
The Tier 3 service will be asked to collect and report on
a range of variables on each patient to demonstrate
success at 6 and 12months. (BC, 2016).
Framework of quality indicators for healthcare business
cases
The seven qualitatively derived quality indicators are
presented within the framework in Fig. 2. Although
quality indicators have been highlighted and described
individually, they should be viewed as distinct yet inter-
related concerns. For example, a business case would be
enriched if it discussed the associated ‘risks’ when out-
lining alternative ‘options’. Further, the framework does
not describe a sequential order in which the quality indi-
cators should be addressed. In practice, questions sur-
rounding how the impact of a business case’s proposal
should be ‘evaluated’ should be considered in advance.
Further, the ‘purpose’ of a proposed change in practice
should be clear throughout a business case, not simply
at the beginning.
Discussion
Main findings and interpretation
This document analysis has identified and amalgamated
insight from expert guidance and current practice to de-
velop a set of key quality considerations for the develop-
ment of business cases in healthcare settings (Fig. 2).
The seven themes derived from this analysis (purpose,
strategic priorities, options, benefits, costs, risks and
evaluation) have been organised into a framework to
support the development and interpretation of business
cases. To our knowledge, this is the first framework of
business case quality indicators, designed specifically for
use in a healthcare context. The extent to which the
NHS business cases we analysed addressed these quality
indicators varied. For example, beyond simply stating
what the risks of the proposed programme are, greater
quality was indicated by also outlining how these risks
will be mitigated. Similarly, beyond presenting the pro-
posed service as the only option, the more comprehen-
sive business cases detailed alternative courses of action,
including the consequences anticipated if ‘no change’
were to be implemented. Longer business cases were not
necessarily any better at providing full coverage of the
quality indicators, indicating that length alone does not
necessarily guarantee quality. Consequently, it would be
beneficial to structure the development of business cases
around a defined set of critical quality considerations,
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rather than writing at length without clear focus on the
most useful information for decision-making.
One of the key links between this research and the
wider literature on healthcare improvements is the im-
portance of evaluation in the context of implementation.
Evaluative evidence should influence changes in practice
[27], however this research also highlights that it is
important to evaluate the implementation of changes to
healthcare practice, to assess the occurrence of expected
(and unexpected) outcomes. Evaluation methods should
be appropriately tailored to improvement initiatives [28],
with plans outlined to describe how any evidence gener-
ated will inform future practice. Comprehensive guid-
ance on the use of quantitative and qualitative methods
to capture outcomes and lessons learned as innovations
are being implemented is available in the literature [29],
and could be used in connection with the model pro-
posed in this research.
In this study, the strategic priorities within the NHS
business cases that we analysed were more likely to re-
flect regional strategies such as those outlined within
Joint Strategic Needs Assessments [30], rather than
international objectives [31]. Intuitively, business case
authors may choose to emphasise how their intended
innovations match the scope of priorities they anticipate
decision-makers responsible for funding will be most
focussed on (in this case the objectives of NHS clinical
commissioners). Although heterogeneity in the chal-
lenges prioritised across health-systems is expected,
numerous global public health concerns, such as the
successful management of antimicrobial resistance re-
quire coordinated and collective action from healthcare
providers internationally [32].
Implications
These findings have implications for how health-related
business cases are compiled, evidenced, and evaluated.
This analysis suggests that authors developing business
cases should prioritise the inclusion of information and
evidence concerning the purpose, strategic priorities,
options, benefits, costs, risks and evaluation of a service or
programme. Although use of this framework in practical
settings such as NHS CCGs has currently not been tested,
constructing business cases in line with these quality indi-
cators provides a structured way of addressing the con-
cerns highlighted by several sources of best practice
expert advice. Through this process of critical reflection,
business cases may be strengthened through greater
clarity, or undergo comprehensive redevelopment.
Strengths and limitations
The main strength of the research was its novel integra-
tion of both top down (expert guidance) and bottom up
(existing business cases) influences. The integration of
expert guidance harnesses best-practice knowledge, and
the influence of existing business cases ensures that the
framework reflects examples from current practice in
decision making (external validity). The use of document
analysis minimises the opportunity for ‘researcher con-
tamination’ in the production of data as (unlike inter-
views and focus groups) documents are exact and have
stable content [18]. Conventionally, qualitative studies
are rarely exclusively dependent on documents as data,
however, given this study’s focus on written business
cases, document analysis combined with thematic ana-
lysis provided an appropriate and flexible methodo-
logical foundation for interpretation.
One limit on the generalisability of the study is that
the NHS business cases we analysed were developed in
one geographical region. Due to the confidential and
sensitive nature of business cases, it was not feasible to
source documents from numerous CCGs. The use of
Clinical Commissioning Group business cases also indi-
cates that further work is needed to explore and incorp-
orate a focus on public health business cases developed
externally to the NHS. Additionally, it would be inform-
ative to explore the relevance of this model across health
systems internationally. Further, we collected business
cases retrospectively, therefore we relied on the content
of meeting minutes to gain a deeper understanding of
the decision-making context. Observing the meetings
first-hand would have provided a richer understanding
of the decision-making process and should be explored
in future research. Finally, although we were able to
develop a framework informed by a rich and in-depth
qualitative analysis, we did not use systematic review
methods to collect the documents providing data, which
is a recognisable methodological limitation.
Future research
The framework of quality indicators presented in this
paper has been developed in accordance with available
expert guidance and existing business cases, however
there remains a need to test the use of the framework in
practice. Future study might therefore qualitatively ex-
plore the addition of other, currently absent, quality indi-
cators. In this way, researchers may move beyond
focusing on how evidence fails to get into practice and
towards responding to the complexity of decision-
making and exploring the ways to facilitate the mobilisa-
tion of knowledge and evidence [33]. Given the recog-
nised importance of critical appraisal tools for assessing
quality [34], a worthwhile focus for future study would
be examining the feasibility of structuring a critical
appraisal checklist for healthcare business cases around
the emergent themes from this research. It would also
be beneficial to explore the role that contextual factors
(such as organisational culture and capacity) might play
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in dictating the success of funded business cases once
plans are implemented into practice.
Although business cases are used to allocate resources
in numerous healthcare settings internationally, alterna-
tive decision-making strategies exist. Considering the
varying quality of the business cases in use, future work
is required to explore whether business cases are an
appropriate method for allocating healthcare resources.
Although business cases provide flexible and ad hoc op-
portunities for innovation, there may be more efficient
and evidence-based methods for introducing service im-
provements. In future research, it would be interesting
to compare and contrast the use of business cases with
other strategies such as Programme Budgeting and Mar-
ginal Analysis [35] or Multi-Criteria Decision Analysis
[36], although these methods tend to be used as part of
a comprehensive priority setting exercise when a num-
ber of options are considered simultaneously, rather
than the more piecemeal decision-making that might be
associated with use of business cases. Such research
would help to build a more comprehensive and com-
parative understanding of the strengths and weaknesses
of these alternative approaches.
This research highlights multiple, potentially competing
priorities to be addressed within the development of
healthcare business cases. Further research is required to
investigate how decision makers trade off on the import-
ance of these multiple competing priorities, and the ra-
tionale that drives this process of prioritisation. For
example, how do CCGs understand and balance pressures
to innovate with the need to address local population
needs and demands (e.g., using evidence within Joint Stra-
tegic Needs Assessments), whilst also factoring in re-
sources to evaluate the impact of changes in practice.
Discrete choice experiments could be used to examine
stated preferences among different stakeholders (health-
care practitioners, decision makers and patients) around
the importance of evidence for each of the quality indica-
tors within the framework presented in this paper [37].
Conclusion
The use of business cases in healthcare facilitates the allo-
cation of limited resources to services and programmes
presented in the form of comprehensive evidence-based
proposals. This study provides a set of qualitatively de-
rived key quality indicators for clinicians and decision
makers tasked with constructing and interpreting business
cases. Future work to investigate the feasibility and poten-
tial usefulness of developing this framework into a critical
appraisal checklist would have further implications for
practice and policy. Future research should explicitly in-
vestigate the extent to which healthcare decision-making
is enhanced through the use of business cases influenced
by the guidance presented in this paper, or whether other
approaches should be encouraged.
Abbreviations
BCs: Business cases; CCGs: Clinical Commissioning Groups; GDs: Guidance
documents; NHS: National Health Service; SMART: Specific, Measurable,
Achievable, Realistic and Timely; SRQR: Standards for Reporting Qualitative
Research; STPs: Sustainability and Transformation Partnerships
Acknowledgements
We would like to acknowledge the valuable comments made by attendees
at the 12th biennial International Society on Priorities in Health (ISPH)
Conference in Linköping, where this research was first presented. We also
thank the CCG staff who facilitated access to business cases for our analysis.
We also thank Dr. Jonathan Roberts for providing useful insight and
feedback on the content and construction of the new framework.
Authors’ contributions
MJL led the data collection, analysis, results writing, graphic representation,
and redrafting. AOS contributed to the data collection, analysis, writing and
drafting of the paper. JC1 contributed to the project initiation, writing,
manuscript elaboration and redrafting. IW contributed to the writing,
manuscript elaboration and redrafting. JC2 contributed to the project
initiation, data collection, manuscript elaboration, and re-drafting. All authors
read and approved the final manuscript.
Funding
This research was funded by the National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health Research and Care West
(NIHR CLAHRC West). The views expressed in this article are those of the
author(s) and not necessarily those of the NHS, the NIHR, or the Department
of Health and Social Care.
Availability of data and materials
The data that support the findings of this study are available from
(Anonymised) CCG but restrictions apply to the availability of these data,
which were used under license for the current study, and so are not publicly
available. Data are however available from the authors upon reasonable
request and with permission of (Anonymised) CCG.
Ethics approval and consent to participate
Ethical approval was obtained from the University of Bristol Faculty of Health
Sciences Research Ethics Committee (Reference: 46563).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Health Economics at Bristol, Population Health Sciences, Bristol Medical
School, University of Bristol, Bristol, UK. 2The National Institute for Health
Research Collaboration for Leadership in Applied Health Research and Care
West (NIHR CLAHRC West) at University Hospitals Bristol NHS Foundation
Trust, Bristol, UK. 3Health Services Management Centre, University of
Birmingham, Birmingham, UK. 4Bristol City Council, Bristol, UK.
Received: 14 January 2019 Accepted: 17 June 2019
References
1. Marmor TR, Klein R. Politics, health, and health care: selected essays.
Dordrecht: Yale University Press; 2012.
2. Lavis JN, Oxman AD, Lewin S, Fretheim A. SUPPORT tools for evidence-
informed health policymaking (STP) 3: setting priorities for supporting
evidence-informed policymaking. Health Research Policy and Systems. 2009;
7(1):S3.
3. Langlois EV, Montekio VB, Young T, Song K, Alcalde-Rabanal J, Tran N.
Enhancing evidence informed policymaking in complex health systems:
Linton et al. BMC Health Services Research          (2019) 19:433 Page 8 of 9
lessons from multi-site collaborative approaches. Health research policy and
systems. 2016;14(1):20.
4. Oliver K, Innvar S, Lorenc T, Woodman J, Thomas J. A systematic review of
barriers to and facilitators of the use of evidence by policymakers. BMC
Health Serv Res. 2014;14(1):2.
5. Carroll AB, Shabana KM. The business case for corporate social responsibility: a
review of concepts, research and practice. Int J Manag Rev. 2010;12(1):85–105.
6. Robinson G, Dechant K. Building a business case for diversity. Acad Manag
Perspect. 1997;11(3):21–31.
7. Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P,
Engelgau MM, Ratner RE, Herman WH. An evaluation of cost sharing to
finance a diet and physical activity intervention to prevent diabetes.
Diabetes Care. 2006;29(6):1237–41.
8. Robinson H, Carrillo P, Anumba C, Al-Ghassani A. Developing a business
case for knowledge management: the IMPaKT approach. Construction
Management & Economics. 2004;22(7):733–43.
9. Harris C, Green S, Elshaug AG. Sustainability in health care by allocating resources
effectively (SHARE) 10: operationalising disinvestment in a conceptual framework
for resource allocation. BMC Health Serv Res. 2017;17(1):632.
10. Charmel P, Frampton SB. Building the business case for patient-centered
care. Healthcare Financial Management. 2008;62(3):80–5.
11. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN, Cosgrove SE.
Raising standards while watching the bottom line making a business case for
infection control. Infection Control & Hospital Epidemiology. 2007;28(10):1121–33.
12. Edwards C, Robinson O. Evaluating the business case for part-time working
amongst qualified nurses. Br J Ind Relat. 2004;42(1):167–83.
13. Nanda U, Eisen S, Zadeh R, Owen D. Effect of visual art on patient anxiety
and agitation in a mental health facility and implications for the business
case. J Psychiatr Ment Health Nurs. 2011;18(5):386–93.
14. Kuper M, Gold SJ, Callow C, Quraishi T, King S, Mulreany A, Bianchi M,
Conway DH. Intraoperative fluid management guided by oesophageal
Doppler monitoring. Bmj. 2011;342:d3016.
15. Robertson R, Wenzel L, Thompson J, Charles A. Understanding NHS financial
pressures: how are they affecting patient care. London: The Kings Fund;
2017.
16. Writing a business case for dermatology services. http://www.bad.org.uk/
healthcare-professionals/clinical-services/writing-a-business-case. Accessed
May 2017.
17. Galloway M. Best practice no 177: best practice guideline: writing a business
case for service development in pathology. J Clin Pathol. 2004;57(4):337–43.
18. Bowen GA. Document analysis as a qualitative research method. Qual Res J.
2009;9(2):27–40.
19. O’brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for
reporting qualitative research: a synthesis of recommendations. Acad Med.
2014;89(9):1245–51.
20. Reiter KL, Kilpatrick KE, Greene SB, Lohr KN, Leatherman S. How to develop
a business case for quality. Int J Qual Health Care. 2006;19(1):50–5.
21. The green book: appraisal and evaluation in central government. https://
www.gov.uk/government/publications/the-green-book-appraisal-and-
evaluation-in-central-governent. Accessed May 2017.
22. Parkinson's service improvement business case checklist (England). https://
www.parkinsons.org.uk/professionals/resources/parkinsons-service-
improvement-business-case-checklist. Accessed May 2017.
23. Building your business case – step by step. https://www.bhf.org.uk/for-
professionals/healthcare-professionals/commissioning-and-services/business-
case-toolkit. Accessed May 2017.
24. Business case approval process – capital investment, property, equipment
and ICT. https://www.england.nhs.uk/resources/bus-case/. Accessed May
2017.
25. Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: striving to
meet the trustworthiness criteria. Int J Qual Methods. 2017;16(1):
1609406917733847.
26. Morse JM. The significance of saturation. Qual Health Res. 1995;5(2):147–9.
27. McDonnell A, Wilson R, Goodacre SJB. Evaluating and implementing new
services. 2006;332(7533):109–12.
28. Parry G, Coly A, Goldmann D, Rowe AK, Chattu V, Logiudice D, Rabrenovic
M, Nambiar BJIJQHC. Practical recommendations for the evaluation of
improvement initiatives. 2018;30(suppl_1):29–36.
29. Balasubramanian BA, Cohen DJ, Davis MM, Gunn R, Dickinson LM, Miller WL,
Crabtree BF, Stange KCJIS. Learning evaluation: blending quality
improvement and implementation research methods to study healthcare.
innovations. 2015;10(1):31.
30. Tomlinson P, Hewitt S, Blackshaw N. Joining up health and planning: how
joint strategic needs assessment (JSNA) can inform health and wellbeing
strategies and spatial planning. Perspectives in Public Health. 2013;133(5):
254–62.
31. Mensah Abrampah N, Syed SB, Hirschhorn LR, Nambiar B, Iqbal U, Garcia-
Elorrio E, Chattu VK, Devnani M, Kelley E. Quality improvement and emerging
global health priorities. Int J Qual Health Care. 2018;30(suppl_1):5–9.
32. Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, Cohen J, Findlay
D, Gyssens I, OJNm H, et al. The global threat of antimicrobial resistance:
science for intervention. 2015;6:22–9.
33. Oliver K, Lorenc T, Innvær S. New directions in evidence-based policy
research: a critical analysis of the literature. Health Research Policy and
Systems. 2014;12(1):34.
34. Katrak P, Bialocerkowski AE, Massy-Westropp N, Kumar VS. Grimmer KA. A
systematic review of the content of critical appraisal tools. BMC Med Res
Methodol. 2004;4(1):22.
35. Ruta D, Mitton C, Bate A, Donaldson C. Programme budgeting and marginal
analysis: bridging the divide between doctors and managers. BMJ. 2005;
330(7506):1501.
36. Baltussen R, Niessen L. Priority setting of health interventions: the need for
multi-criteria decision analysis. Cost effectiveness and resource allocation.
2006;4(1):14.
37. Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to
value health and health care, vol. 11: Springer Science & Business Media;
2007.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Linton et al. BMC Health Services Research          (2019) 19:433 Page 9 of 9
